Metabolic and endocrinology clinical trials, especially GLP-1 and diabetes studies, depend on eCOA to capture continuous, high-volume patient data without compromising accuracy or adherence.
These trials are inherently complex. Daily reporting, long study durations, global execution, and increasing reliance on device-derived endpoints create sustained pressure on both participants and sites. When execution breaks down, the impact is immediate: missed data, declining compliance, and increased operational risk.
Strong outcomes require eCOA that performs consistently over time, supporting participants, adapting to change, and maintaining data integrity at scale.
Why Metabolic Trials Require Specialized eCOA.
Expand your capabilities without expanding headcount. YPrime brings nearly two decades of specialized expertise that complements your organization’s strengths. Our therapeutic area knowledge, instrument licensing relationships, and global regulatory compliance experience fill critical gaps in your portfolio, enabling you to confidently pursue opportunities in new therapeutic areas with a complete technology suite that addresses the full patient journey.
Sustain engagement across long-duration GLP-1 and diabetes studies
Support diverse device-driven endpoints across protocols and regions
Accommodate protocol changes without introducing disruption
Case Study:
Proven in Global Rare Disease Studies
Challenge
A global pharmaceutical sponsor initiated a multi-country GLP-1 clinical trial across multiple metabolic indications. The study required frequent glucose reporting, broad geographic enrollment, and the ability to adjust engagement strategies mid-study to preserve compliance and data quality.
YPrime Solution
YPrime supported the trial using its eCOA platform to:
- Deploy a Bluetooth-enabled blood glucose monitoring diary
- Support thousands of participants globally, including pediatric populations
- Introduce BYOD functionality mid-study to improve participant adherence
- Deploy a Bluetooth-enabled blood glucose Deliver multilingual configurations to enable global expansion
Outcome
The sponsor maintained continuity while expanding internationally. Participant compliance improved, and sites reported strong usability and confidence in execution. Post-study feedback showed the majority of sites reported a positive experience compared with industry benchmarks, reinforcing reliability and operational trust.
How YPrime Supports Metabolic and Endocrinology Studies
YPrime delivers high-quality, flexible eCOA that supports global clinical trials across adult and pediatric populations. Our experience supporting metabolic trials, including GLP-1 and diabetes, is grounded in practical, study-proven execution:
Daily and event-driven eCOA reporting for blood glucose, symptoms, and treatment experience
Blood glucose monitoring with Bluetooth integration reduces manual entry and improves accuracy
Flexible eCOA device strategies, including participant-provided (BYOD) and provisioned models
Mid-study adaptability, including seamless expansion of eCOA device strategies, without trial disruption
Accommodate protocol changes without introducing disruption
Designed for Participants and Sites
Metabolic trials require clarity at every level of execution. Participants must have clear visibility into daily tasks, upcoming activities, and completion status, supporting sustained engagement. Sites need real-time insight into compliance, missing data, and participant progress. This alignment reduces friction and strengthens data quality across the study lifecycle.
FAQs
eCOA (electronic Clinical Outcome Assessment) is used to capture patient-reported data such as blood glucose levels, symptoms, and treatment experience, in real time. It replaces paper-based methods, improving data accuracy, reducing missing entries, and supporting consistent reporting across long-duration studies.
These trials require continuous data collection over extended periods, often combined with device-generated data. eCOA supports this by reducing participant burden, improving adherence, and providing real-time visibility into compliance and data quality.
YPrime’s eCOA platform integrates with devices such as Bluetooth-enabled blood glucose meters, allowing data to flow directly into the study system. This reduces manual entry, improves accuracy, and supports flexible eCOA device strategies, including BYOD and provisioned models.